Phone Interview Research Study for TTR FAP Patients
Phone interview research study for patients diagnosed with Transthyretin Familial Amyloid Polyneuropathy (TTR FAP) to support a new drug development program for treatment of TTR-FAP.
The purpose of this phone interview research study is to gather information about the symptoms and experiences of patients with Transthyretin Familial Amyloid Polyneuropathy (TTR FAP) and to pilot test a questionnaire for future research studies to develop a new drug for the treatment of TTR-FAP. The interview would last approximately 60 minutes, and you would be compensated for your time. There is no medication administration involved with this study. This study is sponsored by GlaxoSmithKline. This study will be conducted by ICON, a health research organization. Please note that GlaxoSmithKline will not receive any identifying information, and any information that you provide will be reported in a way that protects your privacy and anonymity.
Contact:
For more information about this study, please email France G. Sowell at 00180680-NorfolkQoL@iconplc.com or call 1-866-893-0282
- Categories
- Lastest Posts
- FDA Approves Attruby™ (acoramidis) for the Treatment of ATTR-CM: A New Option for Patients
- ARC Launches Clinical Fellowship Program to Advance Amyloidosis Care
- The More Things Change, the More They Stay the Same
- The Inflation Reduction Act: The Devil is in the Details for Patients with Rare Diseases
